Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K LaczikaU Jaeger

Abstract

(1) Quantification of minimal residual disease (MRD) by competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction (RT-PCR) in patients with acute myeloid leukemia (AML) and inversion(16) [inv(16)] during postremission therapy, (2) comparison of this method with conventional two-step RT-PCR, and (3) evaluation of a potential prognostic value. MRD of six consecutive adult patients with AML and inv(16)(p13;q22) or t(16;16)(p13;q22) who entered complete remission (CR) was monitored by competitive CBFbeta/MYH11 RT-PCR in their bone marrow (BM) during postremission therapy with high-dose cytarabine (HiDAC) or after BM transplantation with a matched unrelated-donor marrow (MUD-BMT) during an observation period of 4.5 to 27 months after initiation of treatment. Competitive PCR showed a gradual decline by at least 4 orders of magnitude after 7 to 9 months in patients in continuous CR (CCR), while one patient who relapsed after 13.5 months only achieved a reduction by 2 orders of magnitude at the end of consolidation therapy. A rapid decrease below the detection limit was observed within 1 month in two patients after MUD-BMT. A temporary reappearance of molecular MRD was observed in these patients during immunosuppression...Continue Reading

Citations

Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen KrauterGerhard Heil
Aug 22, 2003·European Journal of Haematology·Guido MarcucciClara D Bloomfield
Nov 5, 1999·Current Opinion in Hematology·T Lion
Mar 14, 2003·Annals of Hematology·U Jaeger, B Kainz
Jul 6, 2000·Current Opinion in Hematology·E L Sievers, J P Radich
Aug 5, 2003·Current Oncology Reports·John A Liu Yin, Lindsay Frost
Jul 26, 2002·British Journal of Haematology·Bert A van der ReijdenJoop H Jansen
Mar 5, 2003·Leukemia & Lymphoma·Wolfgang R SperrPeter Valent
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wolfgang R SperrPeter Valent
May 4, 2002·Best Practice & Research. Clinical Haematology·J A Liu Yin
Oct 11, 2005·Critical Reviews in Oncology/hematology·Wolfgang KernSusanne Schnittger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.